Minimize
 

RTOG 1221 Protocol Information

Minimize
Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer
Protocol Documents
Current Version Date: 8/19/2014
Principal Investigator: Floyd Christopher Holsinger, MD, FACS
Primary Objective:

To determine if primary treatment with transoral endoscopic head and neck surgery will improve PFS for patients with HPV- OPC.

Patient Population:

Squamous cell carcinoma of the oropharynx (localized to the tonsil, glossopharyngeal sulcus, and tongue-base); clinical stage III-IV; T1-2, N1-2b; not approaching within 1 cm of midline, and amenable to transoral eHNS; patient tumor must be p16 negative

Target Accrual: 144
Current Accrual:
Status: Terminated
Date: 2/11/2015
Participating Sites:
Fox Chase Cancer Center Philadelphia PA
Greater Baltimore Medical Center Baltimore MD
Henry Ford Hospital Detroit MI
Mercy Hospital Springfield Springfield MO
Nebraska Methodist Hospital Omaha NE
Siteman Cancer Center at Saint Peters Hospital St. Peters MO
Siteman Cancer Center at West County Hospital St. Louis MO
Siteman Cancer Center-South County St Louis MO
Stanford Cancer Institute Palo Alto Palo Alto CA
Washington University School of Medicine St. Louis MO
Updated: 2/16/2015

You must be logged in to view this file.

Login  |  Close

You must be logged in to view this file.

Login  |  Close